Why the study?
Does rivaroxaban prevent spontaneous coronary thrombosis in patients with thrombophilia due to prothrombin mutation?
Case Report (n=1)
No
Does rivaroxaban prevent spontaneous coronary thrombosis in patients with thrombophilia due to prothrombin mutation?
Factor Xa inhibition by NOACs like rivaroxaban may be insufficient to prevent spontaneous coronary thrombosis in patients with a thrombophilic state due to prothrombin mutation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Calzi et al. (2016) conducted a case report in Acute myocardial infarction with thrombophilia (n=1). Rivaroxaban was evaluated on Spontaneous coronary thrombosis (acute myocardial infarction).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: